Knowles Corporation’s investor presentation targets 8-10% revenue CAGR and 10-14% adjusted EBITDA CAGR, with 16-20% cash from operations as a % of revenue. The presentation also reports $593M in 2025 revenue.
KN · Knowles Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Knowles Corporation reported third-quarter 2026 revenue of $184.0 million, up 20.3%, and nine-month revenue of $503.9 million, up 16.9%. Growth reflected higher demand in electrification, industrial, defense and medtech markets and higher pricing.
Knowles reported third quarter 2026 revenue of $184 million, up 20% year-over-year, EPS of $0.38 and operating cash flow of $45 million. It guided fourth-quarter 2026 revenue between $180 and $190 million and expected full-year 2026 revenue growth of 16 percent.
Knowles Corporation reported Q3 2026 revenue of $184 million, up 20% year over year, and full-year 2026 revenue estimated at $689 million. Q4 2026 revenue outlook was $180 to $190 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 22, 2026TL;DR. Q3 revenue grew 20% to $184 million, non-GAAP EPS increased 15% to $0.38 and operating cash flow was $45 million; Q4 revenue is guided to $180–$190 million, full-year revenue is estimated at $689 million, Precision Devices grew 33%, and management expects its 2027 revenue and adjusted EBITDA growth targets to be exceeded. Offsets include a 210-basis-point decline in MedTech and Specialty Audio adjusted EBITDA margin, capacity constraints, a 2%–3% stamping headwind, higher planned capital spending and operating expenses, and disclosed tariff, material-cost, inventory, inflation and customer-concentration risks.
- + Q3 revenue increased 20% to $184 million and exceeded the high end of guidance, while non-GAAP EPS increased 15% to $0.38 and operating cash flow was $45 million.
- + Management expects Knowles to continue exceeding its 2027 revenue and adjusted EBITDA growth targets.
- + Precision Devices revenue grew 33% to $117 million, with a Q3 book-to-bill ratio of 1.5.
- + Knowles repurchased $25 million of shares and reduced outstanding bank borrowings by $15 million while funding organic growth.
- − Capacity constraints are expected to limit Precision Devices to roughly flat sequential growth despite strong year-over-year growth.
- − Capital spending is expected to increase from the historic range of 3%–5% of revenue to 5%–7% in 2027.
- − The exit of the stamping business is expected to create a 2%–3% MedTech and Specialty Audio revenue headwind in 2027, weighted toward the first half.
- − R&D expense rose $1 million and SG&A expense rose $4 million year over year in Q3.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings before interest, income taxes, depreciation, and amortization ("Adjusted EBITD non-GAAP | 32.2M | Quarter Ended September 30, 2026 | — |
| Adjusted earnings from continuing operations before interest and income taxes non-GAAP | 108.6M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted earnings from continuing operations before interest and income taxes as % of revenues non-GAAP | 21.6% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted EBITDA as a % of revenues non-GAAP | 24.9% | Nine Months Ended September 30, 2026 | — |
| Adjusted free cash flow non-GAAP | 62.4M | Nine Months Ended September 30, 2026 | — |
| Adjusted free cash flow as a % of revenues non-GAAP | 12.4% | Nine Months Ended September 30, 2026 | — |
| Net Cash from Operations | $45M | Q3 2026 | — |
| Net debt leverage ratio | 0.4 | September 30, 2026 | — |
| Non-GAAP capital expenditures attributable to continuing operations non-GAAP | -24.6M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP gross profit non-GAAP | 228.7M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP gross profit as % of revenues non-GAAP | 45.4% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP net cash attributable to continuing operations non-GAAP | 87M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP operating expenses non-GAAP | 117.6M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP research and development expenses non-GAAP | 28.9M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP selling and administrative expenses non-GAAP | 88.7M | Nine Months Ended September 30, 2026 | — |
| Trailing 12 Month Adjusted EBITDA non-GAAP | 166.7M | September 30, 2026 | — |
| EBIT margin | 14.6% | the second quarter of 2026 filing | — |
| MedTech & Specialty Audio Adjusted earnings from continuing operations before interest and incom non-GAAP | $27.6M | second quarter of 2026 filing | — |
| MedTech & Specialty Audio Adjusted EBIT margin non-GAAP | 40.3% | second quarter of 2026 filing | — |
| MedTech & Specialty Audio EBIT margin | 38.4% | second quarter of 2026 filing | — |
| Non-GAAP effective tax rate from continuing operations non-GAAP | 16.9% | Three Months Ended June 30, 2026 filing | — |
| Precision Devices Adjusted earnings from continuing operations before interest and income taxes non-GAAP | $20.3M | second quarter of 2026 filing | — |
| Precision Devices Adjusted EBIT margin non-GAAP | 20.7% | second quarter of 2026 filing | — |
| Precision Devices EBIT margin | 14.1% | second quarter of 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Electronic Components — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KN
this stock
Knowles Corp
|
$2.74B | +50.8% | +7.2% | 39.9 | 4.4% |
|
APH
Amphenol Corp
|
$186.26B | — | +51.7% | 32.9 | 1.1% |
|
GLW
Corning Inc
|
$91.45B | +21.3% | +19.1% | 43.2 | 1.9% |
|
TEL
TE Connectivity plc
|
$61.20B | -6.2% | +15.2% | 19.3 | 2.0% |
|
MRAAF
Murata Manufacturing Co., Ltd.
|
$54.79B | +34.8% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 15
Knowles Corporation’s investor presentation targets 8-10% revenue CAGR and 10-14% adjusted EBITDA CAGR, with 16-20% cash from operations as a % of revenue. The presentation also reports $593M in 2025 revenue.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KN | -2.2% | -6.7% | -14.1% | -1.7% | +50.8% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -0.5% | -3.2% | -12.7% | +0.4% | +42.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.